Shionogi & Co., Ltd. (4507) Press Release
COVGOZE for Intramuscular Injection (JN.1-adapted), Recombinant Protein COVID-19 Vaccine, Receives Partial Change Approval in Japan
Earlier from Shionogi &
- Shionogi Announces U.S. Government Procurement of Fetroja through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
- Consolidated Financial Results for the First Quarter of Fiscal Year 2026 (IFRS)
- Shionogi Recognizes the Four-Year Anniversary of RADICAVA ORS® (edaravone) for Treatment of ALS
- Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure*